Run Vantage on a live deal
Tell us about a deal on your desk. We’ll set up a free 20-minute call to talk it through and scope the right report — an automated Quick Screen for a fast first read, or a Diligence Report reviewed by a physician and a biomedical engineer.
Factual claims in every report are cited to their sources.
How it works
The Quick Screen is automated: six independent signals on one company, each linked to its source records, for $5,000. The Diligence Report is where a physician and a biomedical engineer review the full read, for $20,000 or within a Vantage License. The first call to scope either one is free.
An automated first read on the target: regulatory posture, clinical evidence, IP, reimbursement, team and competitive position, each linked to its source records. No composite score or verdict. See the Quick Screen →
A full eight-domain read reviewed by Arvind Ravinutala, MD, and Aswini Ravinutala, BME: study design, predicate strategy, freedom-to-operate questions and payer economics. Or included in a Vantage License.
Funds that screen regularly can license Vantage: 20 or 40 Quick Screens plus Diligence Reports each year. See license pricing →
Tell us about the deal
A few details so we can prepare for the call and scope the right report. We reply within one business day.
Prefer to pick a time now? Book 20 minutes with Arvind Ravinutala, MD →
What you can count on
Arvind Ravinutala, MD reads the clinical and regulatory picture; Aswini Ravinutala, BME reads the technology, IP, and manufacturing. Both review every full report.
Share only what you are comfortable sharing until an engagement is agreed. We only ask for what the report needs. Read our data-security posture →
Factual claims in a Vantage report are cited to their sources — FDA filings, ClinicalTrials.gov, SEC EDGAR, USPTO, CMS, and more. If we don't have the evidence, we say so.
Tell us about a live deal, or book 20 minutes to talk through which report or license fits your fund.